Stay updated with breaking news from Nuclear Export. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Free Report) have been given an average recommendation of “Moderate Buy” by the five ratings firms that are presently covering the company, MarketBeat reports. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 12-month […]
NEWTON, Mass., April 1, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. , a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an...
Karyopharm Therapeutics Inc. (KPTI.NASDAQ): Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Karyopharm Therapeutics Inc. | Nasdaq: KPTI | Nasdaq
Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Free Report) passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $1.15 and traded as low as $0.69. Karyopharm Therapeutics shares last traded at $0.77, with a volume of 1,320,715 shares changing hands. Wall Street Analysts Forecast Growth KPTI […]
Presenter SpeechEric Joseph Good afternoon. I'm Eric Joseph, senior biotech analyst with JPMorgan. Our next presenting company is Karyopharm Therapeutics and presenting on behalf of the company to...